Ventricular Ectopic Beat(S), Ventricular Tachycardia
Conditions
Brief summary
This is a single centre study enrolling 15 subjects with structurally normal hearts that are already indicated for a ventricular ablation procedure (VT or PVCs). The purpose is to compare the accuracy of VIVO and to assess its efficacy to decrease procedural time, and ideally, the procedural overall costs, as compared to standard of care ablation procedures. Results will be compared with data from
Detailed description
VIVO TM is a non invasive mapping system which can be used to localize PVC / VT origin prior to the ablative procedure. Subjects scheduled for catheter ablation with VIVO will undergo a CT scan prior to the procedure, which will be used to create a personalized 3D model. This will be merged with a 3D photograph (taken at the start of the procedure) of the ECG electrodes on the subject's torso. Then, the recording of the 12 lead ECG will be imported into the VIVO software. All of this data will be combined via the software and a mathematical algorithm will determine the origin of the arrhythmia. This will show the physician where to perform a successful ablation. After 3 months, the subject will return for follow up and will receive another ECG Holter monitor (ECG recording) to determine ablation success. Subjects will be exited from the study after the 3 month follow up visit. Patients will receive standard clinical care prior to, during and after their scheduled procedure, as well as after being discarded from the trial. Results will be analysed and compared to those from an historical cohort of patients (age / gender matched, undergone the same procedure) ablated by the same operator within the previous 5 years (from a database already collected). Data will be anonymised as per current regulations.
Interventions
DIAGNOSTIC_TESTVIVO non invasive mapping
non invasive pre-procedural localization of PVC / VT origin
Sponsors
Royal Brompton & Harefield NHS Foundation Trust
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects who are at least 18 years or older 2. Subjects who are scheduled for PVC/VT ablation procedure 3. Subjects who have signed an IRB/EC approved Informed Consent Form and applicable subject privacy protection authorization per local law 4. Subjects will be selected without regard to gender or age (unless precluded by local regulatory requirements) 5. Subjects with or without cardiac structural disease
Exclusion criteria
1. Reversible causes of PVC/VT 2. Subjects with recent (within 3 months) acute coronary syndrome 3. Subjects who are contraindicated for CT or MRI (must be able to get one) 4. Subject whose MRI or CT scan does not comply with the requirements of this protocol 5. Subjects who are contraindicated for an electrophysiology procedure and/or fluoroscopy: * INR \> 3.5 * Active infection * Pregnancy: Females of childbearing potential with a positive pregnancy test. 6. Existing mechanical heart valve 7. Subjects with structural cardiac disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction of procedural time (in minutes) | three months | Use of VIVO mapping to localize the PVC / VT origin prior to the catheter procedure in order to change procedural time. Procedural time is meant to be measured in minutes per procedure, and it is normally considered from puncture time to sheaths removal. |
| Safety - absence of acute adverse events using VIVO system for non-invasive mapping | three months | Absence of acute adverse events due to the use of VIVO system during PVC/VT ablation in the cohort of patients enrolled for the study. Acute adverse events are described in section 12 of the study protocol and will be reported in specific forms to the Sponsor and REC. |
| Safety 2 - absence of acute adverse events using VIVO system for mapping and during the whole ablation procedure | three months | Safety endpoint of the entire mapping and ablation strategy, determined by the absence of adverse events (AEs). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| economical outcome: change of procedural costs | three months | To assess economical outcome, which is meant as cost change (in pounds) per number of cases |
| clinical outcome assessed as change of PVCs/VT burden | three months | Count of PVC/VT burden at 3-month follow up Holter (expressed as No. / 24 hours) |
Contacts
Primary ContactSabine Ernst, MD, PhD
Backup ContactIlaria Cazzoli, MD
Outcome results
None listed